Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

@article{King2009EffectOI,
  title={Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial},
  author={Talmadge E. King and Carlo Albera and Williamson Z. Bradford and Ulrich Costabel and Phil Hormel and Lisa H Lancaster and Paul W. Noble and Steven A. Sahn and Javier B Szwarcberg and Michiel Thomeer and Dominique Valeyre and Roland M. du Bois},
  journal={The Lancet},
  year={2009},
  volume={374},
  pages={222-228}
}
BACKGROUND Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment exists. We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis and mild-to-moderate impairment of pulmonary function. METHODS 826 patients with idiopathic pulmonary fibrosis were enrolled from 81 centres in seven European countries, the USA, and Canada. Patients were randomly assigned (double-blind) in a 2:1 ratio… Expand
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
  • V. Cottin
  • Medicine
  • European Respiratory Review
  • 2012
TLDR
Evidence of beneficial effects of pirfenidone treatment was observed with regard to several secondary end-points, including progression-free survival time, categorical FVC change, and mean change from baseline to week 72 in 6MWT distance. Expand
Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ).
TLDR
Inhaled IFN-γ was well tolerated for 7 years and may stabilize fibrotic lung disease and may stabilized fibrosis in a 56-year-old male with biopsy proven usual interstitial pneumonia. Expand
Therapeutic Update in Idiopathic Pulmonary Fibrosis
TLDR
Clinical trials suggest that pirfenidone, an oral antifibrotic agent, N-acetylcysteine, an antioxidant and perhaps anticoagulation, may have some beneficial effect; however, large-scale studies are necessary for confirmation. Expand
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
TLDR
The totality of the data indicates that pirfenidone is able to reduce the rate of decline in lung function, measured as change in per cent predicted forced vital capacity (FVC) or vital capacity, and is associated with an acceptable tolerability and safety profile. Expand
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
TLDR
The CAPACITY programme was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Expand
Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.
TLDR
The analysis supports the view that the value of statements can be realized in the subsequent demonstration of their impact on patient management, which might enable further refinements in a continuous, iterative rediscovery process. Expand
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
TLDR
Positive results were obtained in two almost identical double-blind placebo-controlled studies assessing the effects of pirfenidone on change in forced vital capacity, the primary end point, over a 72-week period. Expand
Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis.
TLDR
IFN-γ is safe in IPF and can be effectively delivered to lung parenchyma and post hoc analysis indicated that the slope of decline in TLC and DLCO reversed after beginning therapy. Expand
Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.
TLDR
Mortality was lower in trials that recruited patients with mild-moderate disease severities only, as compared to trials where patients with severe disease were allowed, and infections were high, both with and without immunosuppression, and were higher in severe disease. Expand
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time
TLDR
This trial focused on two specific molecules, transforming growth factor-β1 and connective tissue growth factor, as the relevant therapeutic molecular targets, responsible for the functional improvement observed in patients with idiopathic pulmonary fibrosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
TLDR
In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Expand
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
TLDR
Long-term treatment with interferon gamma 1b may improve survival and outcome in patients with mild-to-moderate idiopathic pulmonary fibrosis, according to the results of this randomised prospective multicentric study. Expand
Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis.
TLDR
A meta-analysis of randomized controlled trials evaluating the use of interferon (IFN)-gamma1b as treatment for IPF found that IFN-gamma 1b therapy is associated with reduced mortality when the results of multiple studies are combined in a meta- analysis. Expand
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.
TLDR
12 months of treatment with interferon gamma-1b plus prednisolone was associated with substantial improvements in the condition of patients with idiopathic pulmonary fibrosis who had had no response to glucocorticoids. Expand
Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis
TLDR
A comparison of mortality at different time points revealed that IFN-γ1b therapy was associated with significantly reduced mortality at 1 year, 18 months, and 1 year after treatment, when the results of multiple studies are combined in a metaanalysis. Expand
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
TLDR
It is concluded that mortality is the most inclusive end point for future trials of IFN- gamma1b in patients with IPF, and that a > 10% decrement in the percentage of predicted FVC represents a valid measure of disease progression. Expand
Effects of Interferon-γ 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis
TLDR
Changes in biomarkers of fibrosis, angiogenesis, proliferation, immunomodulation, and antimicrobial activity suggest that IFN1b may affect IPF through multiple pathways. Expand
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
TLDR
The data suggest that a gradual, progressive decline does not occur in many patients with idiopathic pulmonary fibrosis, thereby supporting the need for early referral for lung transplantation. Expand
A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group.
TLDR
For patients with chronic granulomatous disease, interferon gamma therapy is an effective and well-tolerated treatment that reduces the frequency of serious infections. Expand
Determinants of survival in idiopathic pulmonary fibrosis.
TLDR
To identify the determinants of survival in patients with idiopathic pulmonary fibrosis (IPF), a survival analysis on 74 subjects with IPF demonstrated that diminished survival was significantly associated with male gender. Expand
...
1
2
3
4
...